User banner image
User avatar
  • admin

Posts

/C O R R E C T I O N — Ranok Therapeutics/

In the news release, Ranok Therapeutics Announces Positive Interim Phase 1 Data Of Its KRAS G12D Inhibitor RNK08954 In Patients With KRAS G12D-Mutated Metastatic Non-Small...

Blue Sky and Sincerely Jules Bring Vintage Style to Academic Planners at Staples

IRVINE, Calif., June 01, 2026 (GLOBE NEWSWIRE) — Blue Sky, the #1 dated goods brand in the US, announces its academic collection with Los Angeles-based...

Waldencast Announces Sale of Obagi Medical to Bridgepoint

LONDON, June 01, 2026 (GLOBE NEWSWIRE) — Waldencast plc (NASDAQ: WALD) (“Waldencast” or “the Company”) today announced that it has entered into a definitive agreement...

EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) — EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with...

NVIDIA and Microsoft Reinvent Windows PCs for the Age of Personal AI

RTX Spark — a 1-Petaflop Superchip, the Full CUDA and RTX Ecosystem, and Windows-Native Agents — a New Beginning for Personal Computers News Summary: NVIDIA...

NurExone Announces First Quarter 2026 Financial Results and Provides Corporate Update

TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a...

Dr. Falk Pharma and Renexxion Proceed to Late-Stage Development of Naronapride, Moving Towards Approval in the US and Europe, Following Positive Global Phase 2b Results in Gastroparesis

Renexxion plans to file new drug application (NDA) with the Food and Drug Administration (FDA) using future Phase 3 results  ROSCREA, Ireland and FREIBURG, Germany,...

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

One-time infusion of anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy induced rapid, deep and durable systemic anti-tumor activity in metastatic PD-1 relapsed cutaneous melanoma and...

Intravacc and Primrose Bio Renew Partnership to Enhance Conjugate Vaccine Development

The companies will leverage their combined experience in the development of conjugate vaccines for their clients Primrose Bio will supply its industry-leading carrier protein, PeliCRM197®,...

Senseonics Highlights Analyst Event and Oral Presentation of Eversense 365 Real-World Evidence at ADA 2026

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) — Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of...